Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Other
Ratios

Barinthus Biotherapeutics (BRNS) Receivables Refunds (2020 - 2023)

Barinthus Biotherapeutics (BRNS) has disclosed Receivables Refunds for 4 consecutive years, with $1.7 million as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Receivables Refunds changed N/A year-over-year to $1.7 million, compared with a TTM value of $1.7 million through Sep 2023, changed N/A, and an annual FY2021 reading of $705000.0, up 131.15% over the prior year.
  • Receivables Refunds was $1.7 million for Q3 2023 at Barinthus Biotherapeutics, up from $1.0 million in the prior quarter.
  • Across five years, Receivables Refunds topped out at $1.7 million in Q3 2023 and bottomed at $55000.0 in Q3 2021.
  • Average Receivables Refunds over 4 years is $647500.0, with a median of $505000.0 recorded in 2020.
  • The sharpest move saw Receivables Refunds skyrocketed 131.15% in 2021, then surged 1248.68% in 2022.
  • Year by year, Receivables Refunds stood at $305000.0 in 2020, then skyrocketed by 131.15% to $705000.0 in 2021, then soared by 45.39% to $1.0 million in 2022, then skyrocketed by 67.71% to $1.7 million in 2023.
  • Business Quant data shows Receivables Refunds for BRNS at $1.7 million in Q3 2023, $1.0 million in Q2 2022, and $705000.0 in Q4 2021.